BioXcel Therapeutics, Inc. Excess Tax Benefit from Share-based Compensation, Financing Activities
BioXcel Therapeutics, Inc. (BTAI) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $22.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2020-03-09
- BioXcel Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2019-12-31 was $21.00K.
- BioXcel Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2019-09-30 was $0.00.
- BioXcel Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2019-06-30 was $0.00.
- BioXcel Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2019-03-31 was $1.00K.
- BioXcel Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2019 was $22.00K, a 214.29% increase from fiscal 2018.
- BioXcel Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2018 was $7.00K.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2019-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $21.00K derived: sum of 2 quarters · filed 2020-03-09 | $21.00K derived: sum of 3 quarters · filed 2020-03-09 | $22.00K 10-K · filed 2020-03-09 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $1.00K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.00K 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $1.00K 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $7.00K 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |